Pentylenetetrazol

Source: Wikipedia, the free encyclopedia.
(Redirected from
Metrazol
)
Pentylenetetrazol
Clinical data
Trade namesMetrazol, others
ATC code
Identifiers
  • 6,7,8,9-Tetrahydro-5H-tetrazolo(1,5-a)azepine
JSmol)
  • C1CCc2nnnn2CC1
  • InChI=1S/C6H10N4/c1-2-4-6-7-8-9-10(6)5-3-1/h1-5H2 ☒N
  • Key:CWRVKFFCRWGWCS-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Pentylenetetrazol, also known as pentylenetetrazole, leptazol, metrazol, pentetrazol (

cough suppressant drug.[3]

Mechanism

The mechanism of pentylenetetrazol is not well understood, and it may have multiple

anticonvulsants, but presumably pentylenetetrazol has the opposite effect when it binds to the GABA-A receptor.[4]

Several studies have focused on the way pentylenetetrazol influences neuronal ion channels. A 1987 study found that pentylenetetrazol increases calcium influx and sodium influx, both of which depolarize the neuron. Because these effects were antagonized by calcium channel blockers, pentylenetetrazol apparently acts at calcium channels, and it causes them to lose selectivity and conduct sodium ions, as well.[5]

Research

Pentylenetetrazol has been used experimentally to study seizure phenomena and to identify pharmaceuticals that may control seizure susceptibility. For instance, researchers can induce

ligands.[6]

See also

References

  1. doi:10.1176/ajp.97.3.667
    .
  2. ^ Minkel JR (February 25, 2007). "Drug May Counteract Down Syndrome". Scientific American. Retrieved 2007-03-20.
  3. ^ "Cardiazol-Paracodina". Agenzia Italiana del Farmaco.
  4. PMID 6090836
    .
  5. PMID 3503442
    .
  6. S2CID 26055062
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pentylenetetrazol&oldid=1112210003"